Inhibition Options in Advanced CRC After Prior Treatment

Retrospective Data Highlight Impact of Dose Escalation of Regorafenib in mCRC

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.

Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.

Regorafenib Continues to Benefit Patients With Advanced CRC

Daniel H. Ahn, DO, discusses how regorafenib continues to benefit patients with advanced colorectal cancer as researchers look to modify treatment strategies with the therapy.